This Market Spotlight report covers the Systemic Hypertension market, comprising key marketed and pipeline drugs, clinical trials, key upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

• Datamonitor Healthcare estimates that in 2017, there were approximately 1.7 billion prevalent cases of systemic hypertension worldwide, and forecasts that number to increase to 1.9 billion prevalent cases by 2026.
• Systemic hypertension has a slight male predominance. Globally, Datamonitor Healthcare estimates that in 2017, 53.31% of cases aged 25 years and over were male.
• The approved drugs in the systemic hypertension space focus on a wide variety of targets. These drugs are commonly administered via the oral route, with a few products being available in intravenous, intramuscular, and transdermal formulations.
• The largest proportion of industry-sponsored drugs in active clinical development for systemic hypertension are in Phase I, with only one drug in the NDA/BLA phase.
• Therapies in development for systemic hypertension focus on a wide variety of targets. The majority of pipeline drugs are administered via the oral route, with the remainder being intranasal, subcutaneous, intravenous, and topical formulations.
• The overall likelihood of approval of a Phase I systemic hypertension asset is 6.4%, and the average probability a drug advances from Phase III is 68.2%. Drugs, on average, take 6.5 years from Phase I to approval, compared to 9.8 years in the overall cardiovascular space.
• There have been 38 licensing and asset acquisition deals involving hypertension drugs during 2014–19. The largest deal was the $792m exclusive agreement between The Medicines Company and Chiesi in 2016 for the sale of Cleviprex injectable emulsion, Kengreal, and the rights to argatroban for injection.
• The distribution of clinical trials across Phase I–IV indicates that the majority of trials for hypertension have been in the late phases of development, with 53% of trials in Phase III–IV, and 47% in Phase I–II.
• The US has a substantial lead in the number of hypertension clinical trials globally. Germany leads the major EU markets, while South Korea has the top spot in Asia.
• Clinical trial activity in the hypertension space is dominated by completed trials. Novartis has the highest number of completed clinical trials for hypertension, with 384 trials. Novartis also leads industry sponsors with by far the highest overall number of clinical trials for hypertension.